ES2049656A1 - Grupos de conjugados de farmacos con anticuerpos. - Google Patents

Grupos de conjugados de farmacos con anticuerpos.

Info

Publication number
ES2049656A1
ES2049656A1 ES9202001A ES9202001A ES2049656A1 ES 2049656 A1 ES2049656 A1 ES 2049656A1 ES 9202001 A ES9202001 A ES 9202001A ES 9202001 A ES9202001 A ES 9202001A ES 2049656 A1 ES2049656 A1 ES 2049656A1
Authority
ES
Spain
Prior art keywords
antibodies
drugs
attach
drug molecules
cytotoxic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES9202001A
Other languages
English (en)
Other versions
ES2049656B1 (es
Inventor
Koppel
Offord
Rose
Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to ES09202001A priority Critical patent/ES2049656B1/es
Publication of ES2049656A1 publication Critical patent/ES2049656A1/es
Application granted granted Critical
Publication of ES2049656B1 publication Critical patent/ES2049656B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION PROPORCIONA UN CONJUGADO FISIOLOGICAMENTE ACEPTABLE DE UN FARMACO DE FORMULA (I), EN LA QUE AC, R, RBS1 SC, X, Z, M, N, P, Q, R, S, Y, RBS2 SC, RBS3 SC Y RBS4 SC SE DEFINEN CON DETALLE EN LA MEMORIA DESCRIPTIVA. TAMBIEN PROPORCIONA COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN CONJUGADO DE LA INVENCION E INTERMEDIOS PARA PREPARAR LOS CONJUGADOS Y UN FARMACO MODIFICADO. REPRESENTA UN PROGRESO SIGNIFICATIVO EN EL CAMPO DE LOS FARMACOS DIRIGIDOS A UN OBJETIVO CONCRETO AL PERMITIR LA FIJACION DE MULTIPLES MOLECULAS DE FARMACO CITOTOXICO A UNA SOLA MOLECULA DE ANTICUERPO, TENIENDO APLICACION EN EL TRATAMIENTO DEL CANCER.
ES09202001A 1992-10-08 1992-10-08 Grupos de conjugados de farmacos con anticuerpos. Expired - Lifetime ES2049656B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES09202001A ES2049656B1 (es) 1992-10-08 1992-10-08 Grupos de conjugados de farmacos con anticuerpos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09202001A ES2049656B1 (es) 1992-10-08 1992-10-08 Grupos de conjugados de farmacos con anticuerpos.

Publications (2)

Publication Number Publication Date
ES2049656A1 true ES2049656A1 (es) 1994-04-16
ES2049656B1 ES2049656B1 (es) 1994-11-16

Family

ID=8278354

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09202001A Expired - Lifetime ES2049656B1 (es) 1992-10-08 1992-10-08 Grupos de conjugados de farmacos con anticuerpos.

Country Status (1)

Country Link
ES (1) ES2049656B1 (es)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4543211A (en) * 1982-12-24 1985-09-24 Teijin Limited Conjugate having cytotoxicity and process for the preparation thereof
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
EP0354728A2 (en) * 1988-08-08 1990-02-14 Eli Lilly And Company Cytotoxic drug conjugates
EP0368668A2 (en) * 1988-11-10 1990-05-16 Eli Lilly And Company Antibody-drug conjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046722A (en) * 1975-02-04 1977-09-06 G. D. Searle & Co. Limited Immunological materials
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4543211A (en) * 1982-12-24 1985-09-24 Teijin Limited Conjugate having cytotoxicity and process for the preparation thereof
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
EP0326322A1 (en) * 1988-01-27 1989-08-02 Eli Lilly And Company Antibody conjugates
EP0354728A2 (en) * 1988-08-08 1990-02-14 Eli Lilly And Company Cytotoxic drug conjugates
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
EP0368668A2 (en) * 1988-11-10 1990-05-16 Eli Lilly And Company Antibody-drug conjugates

Also Published As

Publication number Publication date
ES2049656B1 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
HUP9802339A2 (hu) Darifenacint tartalmazó gyógyászati készítmények
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
BG101118A (en) Therapeutical compounds
PH27416A (en) Stabilized medicine formulations
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
FR2681862B1 (fr) Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
BR0106401A (pt) Mistura de conjugados, composição farmacêutica e processo pra sintetizar uma mistura de conjugados
RU94028670A (ru) Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
ES2090395T3 (es) Formulados farmaceuticos gastroresistentes para administracion por via oral que contienen acidos biliares.
DE69527506D1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
YU35102A (sh) Derivati heterociklo-alkilsulfonil pirazola kao anti- inflamatorni/analgetički agensi
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
GB8827152D0 (en) Anti-atherosclerotic diaryl compounds
FR2375867A1 (fr) Medicament a base de dehydro-oligopeptides destine a la resolution d'une tumeur ou d'un tissu
TR199801614T2 (xx) Peptit t�revleri
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
DK0387821T3 (da) 2-Alkyl-4-arylmethylchinoliner, deres anvendelse og lægemidler fremstillet hermed
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
RU94002476A (ru) Лекарственное средство